{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:41:02Z","timestamp":1768549262509,"version":"3.49.0"},"posted":{"date-parts":[[2020,8,7]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":28,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,8,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Commercial availability of serological tests to evaluate immunoglobulins (Ig) towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has grown exponentially since the onset of COVID-19 (Coronavirus Disease 2019) outbreak. Their thorough validation is of extreme importance before using them as epidemiological tools to infer population seroprevalence, and as complementary diagnostic tools to molecular approaches\n                  <jats:italic>(e.g<\/jats:italic>\n                  . RT-qPCR). Here we assayed commercial serological tests (semiquantitative and qualitative) from 11 suppliers in 126 samples collected from hospitalized COVID-19 patients, and from 36 healthy and HIV-infected individuals (collected at the pre-COVID-19 pandemic). Specificity was above 95% in 9 tests. Samples from COVID-19 patients were stratified by days since symptoms onset (&lt;10, 10-15, 16-21 and &gt;21 days). Tests sensitivity increases with time since symptoms onset, and peaks at 16-21 days for IgM and IgA (maximum: 91.2%); and from 16-21 to &gt;21 days for IgG, depending on the test (maximum: 94.1%). Data from semiquantitative tests show that patients with severe clinical presentation have lower relative levels of IgM, IgA and IgG at &lt;10 days since symptoms onset in comparison to patients with non-severe presentation. At &gt;21 days since symptoms onset the relative levels of IgM and IgG (in one test) are significantly higher in patients with severe clinical presentation, suggesting a delay in the upsurge of Ig against SARS-CoV-2 in those patients.\n                <\/jats:p>\n                <jats:p>This study highlights the high specificity of most of the evaluated tests, and sensitivity heterogeneity. Considering the virus genetic evolution and population immune response to it, continuous monitoring of commercially available serological tests towards SARS-CoV-2 is necessary.<\/jats:p>","DOI":"10.1101\/2020.08.06.20168856","type":"posted-content","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T18:45:31Z","timestamp":1596825931000},"source":"Crossref","is-referenced-by-count":3,"title":["Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalized COVID-19 patients"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3456-6064","authenticated-orcid":false,"given":"C","family":"Serre-Miranda","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0282-9619","authenticated-orcid":false,"given":"C","family":"Nobrega","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-996X","authenticated-orcid":false,"given":"S","family":"Roque","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7499-1500","authenticated-orcid":false,"given":"J","family":"Canto-Gomes","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2701-179X","authenticated-orcid":false,"given":"CS","family":"Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-4336","authenticated-orcid":false,"given":"N","family":"Vieira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8070-1856","authenticated-orcid":false,"given":"P","family":"Barreira-Silva","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6082-6838","authenticated-orcid":false,"given":"P","family":"Alves-Peixoto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0151-4826","authenticated-orcid":false,"given":"J","family":"Cotter","sequence":"additional","affiliation":[]},{"given":"A","family":"Reis","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8105-3144","authenticated-orcid":false,"given":"M","family":"Formigo","sequence":"additional","affiliation":[]},{"given":"H","family":"Sarmento","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-9820","authenticated-orcid":false,"given":"O","family":"Pires","sequence":"additional","affiliation":[]},{"given":"A","family":"Carvalho","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-4076","authenticated-orcid":false,"given":"DY","family":"Petrovykh","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3695-6963","authenticated-orcid":false,"given":"L","family":"Di\u00e9guez","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3249-0035","authenticated-orcid":false,"given":"JC","family":"Sousa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8755-5126","authenticated-orcid":false,"given":"N","family":"Sousa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0450-7103","authenticated-orcid":false,"given":"C","family":"Capela","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8866-368X","authenticated-orcid":false,"given":"JA","family":"Palha","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-4130","authenticated-orcid":false,"given":"PG","family":"Cunha","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-5431","authenticated-orcid":false,"given":"M","family":"Correia-Neves","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"key":"2021020122151479000_2020.08.06.20168856v1.1","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. Available from: https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020"},{"key":"2021020122151479000_2020.08.06.20168856v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)302518"},{"key":"2021020122151479000_2020.08.06.20168856v1.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006100"},{"key":"2021020122151479000_2020.08.06.20168856v1.4","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.4.2000058"},{"key":"2021020122151479000_2020.08.06.20168856v1.5","doi-asserted-by":"crossref","unstructured":"Guo L , Ren L , Yang S , Xiao M , Chang D , Yang F , et al. Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). Clin Infect Dis. 2020;1-28.","DOI":"10.1093\/cid\/ciaa310"},{"key":"2021020122151479000_2020.08.06.20168856v1.6","doi-asserted-by":"crossref","unstructured":"Zhao J , Yuan Q , Wang H , Liu W , Liao X , Su Y , et al. Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. Clin Infect Dis. 2020;1-22.","DOI":"10.1093\/cid\/ciaa344"},{"key":"2021020122151479000_2020.08.06.20168856v1.7"},{"key":"2021020122151479000_2020.08.06.20168856v1.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008536"},{"issue":"1","key":"2021020122151479000_2020.08.06.20168856v1.9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","year":"2020","journal-title":"Cell"},{"key":"2021020122151479000_2020.08.06.20168856v1.10","doi-asserted-by":"crossref","unstructured":"Ju B , Zhang Q , Ge J , Wang R , Sun J , Ge X , et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;","DOI":"10.1101\/2020.03.21.990770"},{"key":"2021020122151479000_2020.08.06.20168856v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16638-2"},{"key":"2021020122151479000_2020.08.06.20168856v1.12","doi-asserted-by":"crossref","first-page":"104413","DOI":"10.1016\/j.jcv.2020.104413","article-title":"Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies","volume":"128","year":"2020","journal-title":"J Clin Virol"},{"key":"2021020122151479000_2020.08.06.20168856v1.13","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/22221751.2020.1756699","article-title":"Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients","volume":"9","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"2021020122151479000_2020.08.06.20168856v1.14","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients","volume":"26","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2021020122151479000_2020.08.06.20168856v1.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.04.026"},{"issue":"2","key":"2021020122151479000_2020.08.06.20168856v1.16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/infdis\/jiaa229","article-title":"Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019","volume":"222","year":"2020","journal-title":"J Infect Dis"},{"issue":"1","key":"2021020122151479000_2020.08.06.20168856v1.17","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1080\/22221751.2020.1773324","article-title":"Patterns of IgG and IgM antibody response in COVID-19 patients","volume":"9","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"1","key":"2021020122151479000_2020.08.06.20168856v1.18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/22221751.2020.1762515","article-title":"Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients","volume":"9","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"2021020122151479000_2020.08.06.20168856v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.012"},{"key":"2021020122151479000_2020.08.06.20168856v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2020.05.049"},{"key":"2021020122151479000_2020.08.06.20168856v1.21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/infdis\/jiaa305","article-title":"Performance of SARS-CoV-2 antibody assays in different stages of the infection: Comparison of commercial ELISA and rapid tests","volume":"222","year":"2020","journal-title":"J Infect Dis"},{"key":"2021020122151479000_2020.08.06.20168856v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30243-7"},{"key":"2021020122151479000_2020.08.06.20168856v1.23","doi-asserted-by":"crossref","unstructured":"Osorio NS , Correia-Neves M . Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays. Lancet Infect Dis. 2020;1-2.","DOI":"10.1016\/S1473-3099(20)30435-7"},{"key":"2021020122151479000_2020.08.06.20168856v1.24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00858"},{"key":"2021020122151479000_2020.08.06.20168856v1.25","unstructured":"Whitman JD , Hiatt J , Mowery CT et al. Test performance evaluation of SARS-CoV-2 serological assays. Preprint. medRxiv. 2020;"},{"key":"2021020122151479000_2020.08.06.20168856v1.26","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.4.2000058"},{"key":"2021020122151479000_2020.08.06.20168856v1.27","doi-asserted-by":"crossref","unstructured":"Kontou PI , Braliou GG , Dimou NL , Nikolopoulos G , Bagos PG . Antibody Tests in Detecting SARS-CoV-2 Infection: Diagnostics. 2020;10(319).","DOI":"10.3390\/diagnostics10050319"},{"key":"2021020122151479000_2020.08.06.20168856v1.28","doi-asserted-by":"crossref","unstructured":"Liu W , Liu L , Kou G , Zheng Y , Ding Y , Ni W , et al. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2. J Clin Microbiol. 2020;","DOI":"10.1101\/2020.03.16.20035014"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.08.06.20168856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:50:44Z","timestamp":1768485044000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.08.06.20168856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1101\/2020.08.06.20168856","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1016\/j.ijid.2021.01.038","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2020,8,7]]},"subtype":"preprint"}}